Beyond improving disease control, adding bevacizumab to chemotherapy in platinum-resistant ovarian cancer offers a significant quality-of-life benefit. Data from the AURELIA study showed it dramatically reduces the need for paracentesis, a procedure to drain malignant ascites (abdominal fluid) that can be detrimental for patients.
A new wave of antibody-drug conjugates (ADCs) is transforming ovarian cancer treatment. These 'heat-seeking missiles' deliver potent chemotherapy payloads directly to tumor cells, achieving response rates from 23% to over 60% in biomarker-selected populations. This far surpasses the efficacy of conventional chemotherapy in resistant settings.
The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.
Despite logistical challenges like clinic chair time, the ICON 8B study's positive results are forcing a re-evaluation of weekly paclitaxel. The trial demonstrated improved progression-free and overall survival compared to the standard three-week cycle, suggesting a potential shift back to a previously debated dose-dense strategy in the frontline setting.
The initial broad enthusiasm for PARP inhibitors in ovarian cancer has been refined. New data confirms a lack of overall survival improvement for patients with HRD-negative (or HR proficient) tumors, pushing clinicians toward a precision medicine approach where these drugs are reserved for patients with BRCA mutations or HRD-positive disease who are most likely to benefit.
The widespread use of PARP inhibitors has altered tumor biology in platinum-sensitive ovarian cancer. A recent meta-analysis of heavily pretreated patients, 97% of whom had prior PARP inhibitor exposure, revealed an objective response rate to subsequent therapy of only 17%—far lower than historical expectations, highlighting a critical unmet clinical need.